Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2009 Jan;4(1):110-8.
doi: 10.2215/CJN.02790608. Epub 2008 Oct 22.

Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients

Juan J Carrero  1 , Alberto Ortiz, Abdul R Qureshi, Jose L Martín-Ventura, Peter Bárány, Olof Heimbürger, Belén Marrón, George Metry, Sunna Snaedal, Bengt Lindholm, Jesús Egido, Peter Stenvinkel, Luis M Blanco-Colio
Affiliations
Multicenter Study

Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients

Juan J Carrero et al. Clin J Am Soc Nephrol. 2009 Jan.

Abstract

Background and objectives: Chronic kidney disease (CKD) is characterized by an exceptionally high mortality rate, primarily due to cardiovascular disease. Reduced soluble TNF-like weak inducer of apoptosis (sTWEAK) plasma levels have been reported both in patients with subclinical atherosclerosis and CKD.

Design, participants, & measurements: A cross-sectional study was conducted in 218 prevalent patients (121 men; 63 +/- 14 yr) undergoing hemodialysis (HD). sTWEAK levels in relation with the patients' outcome were studied.

Results: sTWEAK plasma levels were 208 [(165 to 272) pg/ml, median interquartile range], significantly lower than healthy controls (P < 0.0001). sTWEAK was negatively associated with inflammatory markers, such as C-reactive protein and IL-6. Overall mortality was assessed after an average follow-up of 31 mo, during which 81 patients died. After controlling for potential confounding variables, patients in the upper tertile of sTWEAK plasma levels had an increased risk of cardiovascular and all-cause mortality. A significant interaction effect between sTWEAK and IL-6 levels was found [synergy index: 2.19 (0.80, 5.93)]. Thus, the association of sTWEAK with mortality was strongest in patients with inflammation (defined as IL-6 > 7.0 pg/ml), in whom high sTWEAK strongly predicted cardiovascular and all-cause mortality. These results were confirmed in a second cohort of HD patients.

Conclusions: The concurrent presence of elevated sTWEAK plasma concentrations and an inflammatory environment have additive effects on mortality in HD patients. Further studies on the potential different role of sTWEAK in health and disease are warranted.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Crude and (B) adjusted mortality risk in patients undergoing hemodialysis according to their levels of IL-6 and soluble TNF-like weak inducer of apoptosis (sTWEAK). High sTWEAK was defined as sTWEAK concentration above the 66th percentile (>244 pg/ml). High IL-6 was defined as IL-6 > 7.0 pg/ml (determined by receiver operator characteristic curves). Adjustment of the Cox was done for age, sex, Davies comorbidity score, intake of acetylsalicylic acid, and dialysis vintage.
Figure 2.
Figure 2.
Serum IGF-1 concentration in different sTWEAK/IL-6 groups. Sidak–Ansari post hoc analysis of pair differences at the level of α = 0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112–S119, 1998 - PubMed
    1. Tonelli M, Pfeffer MA: Kidney disease and cardiovascular risk. Ann Rev Med 58: 123–139, 2007 - PubMed
    1. Stenvinkel P, Wanner C, Metzger T, Heimburger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 62: 1791–1798, 2002 - PubMed
    1. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 505–521, 2008 - PMC - PubMed
    1. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright, JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853–906, 1998 - PubMed

Publication types

MeSH terms